ESR11 small

NOVEL CONCEPTS IN SUPPORT OF CLINICAL MANAGEMENT OF AMR

A digital microfluidic platform capable of detecting carbapenem resistance directly from a clinical sample

Carbapenem resistance is on the rise and a significant threat to proper antibiotic treatment. Due to the massive amount of genes and variants involved, such resistance is difficult to adequately capture using molecular diagnostics. Various phenotypic approaches, such as MALDI-TOF and CARBA NP, have been developed. However, these start from a pure culture, which in itself requires a day of prior growth, delaying targeted administration of antibiotics. In this project, the Carba NP test will be adapted for use directly on clinical samples, requiring investigations in bacterial extraction and seeding as well as the comparison of various ultrasensitive detection approaches.

  • University of Antwerp – Vaccine & Infectious Disease Institute
    Campus Drie Eiken – Universiteitsplein 1
    2610 Antwerpen
    Belgium
  • Kungliga Tekniska Högskolan (KTH)
    Micro and nanosystems (MST) department
    Osquldas väg 10, Stockholm
    Sweden
  • bioMérieux
    Innovation Unit-Biology Research Department
    38390 La Balme Les Grottes
    France

Specific profile requirements

  • Strong technical background (bio-engineer, engineer, biochemist,…)
  • Solid knowledge of microbiology
  • Creative and capable of thinking out-of-the box
  • Capable of working independently (planning and executing experiments)
  • Excellent interpersonal skills, team player